CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer

Gynecologic and Obstetric Investigation

Volumn 72, Issue 3, 2011, Pages 203-207

  Wong, Raymond R Y ^a   Chan, Loucia K Y ^a   Tsang, Teresa P T ^a   Lee, Coral W S ^a   Cheung, T H ^a   Yim, S F ^a   Siu, Nelson S S ^a   Lee, Sophia N C ^a   Yu, M Y ^a   Chim, Stephen S C ^a   Wong, Y F ^a   Chung, Tony K H ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CHD5; Downregulation; Ovarian cancer

Indexed keywords

CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HONG KONG; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CASE-CONTROL STUDIES; DNA HELICASES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 80255138705     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000323883     Document Type: Article

References (9)

1. Hong Kong Cancer Registry: Common Cancers: Statistics at a Glance: Ovarian Cancer. Hong Kong Cancer Stat 2007. Hospital Authority, Hong Kong, 2010, pp 15.
2. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM: CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003; 22: 1002-1011. (Pubitemid 36313144)
3. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA: CHD5 is a tumor suppressor at human 1p36. Cell 2007; 128: 459-475. (Pubitemid 46198889)
4. Fugita T: CHD5, a tumor suppressor gene deleted from 1p36.3 in neuroblastoma. J Natl Cancer Inst 2008; 100: 940-949.
5. Imyanitov EN, Birrell GW, Filippovich I, Sorokina N, Arnold J, Mould MA, Wright K, Walsh M, Mok SC, Lavin MF, Chenevix-Trench G, Khanna KK: Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 1999; 18: 4640-4642. (Pubitemid 29405896)
6. Alvarez AA, Lambers AR, Lancaster JM, Maxwell GL, Ali S, Gumbs C, Berchuck A, Futreal PA: Allele loss on chromosome 1p36 in epithelial ovarian cancers. Gynecol Oncol 2001; 82: 94-98. (Pubitemid 32640199)
7. Rao PH, Harris CP, Yan Lu X, Li XN, Mok SC, Lau CC: Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer 2002; 33: 123-132. (Pubitemid 34052493)
8. Panani AD, Roussos C: Non-random structural chromosomal changes in ovarian cancer: i(5p) a novel recurrent abnormality. Cancer Lett 2006; 235: 130-135.
9. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, Campbell IG: Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008; 10: 1253-1258.